RxDoctor Payments DataLook up a doctor →

Dayna Giordano, APRN

Family · New Haven, CTNPI 1811437973

Payments from drug & device makers

$64,982in general payments, 2019–2025

Across 1,379 payments — averaging $47.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$20K
  • AbbVie$19K
  • Idorsia Pharmaceuticals US Inc$5K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$4K
  • Alkermes, Inc.$2K
  • Lundbeck LLC$2K
  • plus $14K from 43 others

What the payments were for

  • Consulting fees$9,42615%
  • Speaking & faculty fees$22,44035%
  • Travel & lodging$2,2093%
  • Food & beverage$30,86047%
  • Education$470%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,982 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$41,467
Medicare patients
54
Services billed
343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl194$240,055
VraylarCariprazine Hcl38$63,922
AuvelityDextromethorphan Hbr/Bupropion19$25,814
XanaxAlprazolam14$19,001
Aripiprazole29$9,071
Duloxetine Hcl53$2,449
Bupropion XlBupropion Hcl68$1,899
Perphenazine17$1,552
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl12$1,446
Quetiapine Fumarate83$1,407
Alprazolam177$1,317
Olanzapine47$1,287
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine32$1,250
Lamotrigine106$1,237
Clonazepam98$1,234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$1,146$240,055194 claims
AbbVieVraylar$18,649$63,92238 claims
Axsome Therapeutics, Inc.Auvelity$20,092$25,81419 claims
Lilly USA, LLCOlanzapine$51$1,28747 claims
Almatica Pharma LLCSertraline Hcl$358$35859 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.

Other family in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →